Pradaxa™ (dabigatran etexilate), a new oral anticoagulant from Boehringer Ingelheim, has been approved for use in South Africa in primary prevention of venous thromboembolic events in adults after elective total hip or knee replacement surgery

"Pradaxa™ (dabigatran etexilate), a new oral anticoagulant from Boehringer Ingelheim, has been approved for use in South Africa in primary prevention of venous thromboembolic events in adults after elective total hip or knee replacement surgery." South African Family Practice, 52(2), pp. 85–86